Serum FABP4 levels were positively associated with suspected liver steatosis assessed by the fatty liver index (FLI) in both normal glucose tolerance subjects [23] and patients at increased cardiometabolic risk, including diabetic, obese, and metabolic syndrome patients [30]. Here, FABP4 is linked to metabolic syndrome.